The round was led by Savitr Capital and Hayfin Capital Management. This significant funding will fuel the continued expansion of Glytec's platform, including its flagship Glucommander® SaaS solution, accelerate the development of innovative new technologies to address the growing global health crisis of diabetes and related co-morbidities, and support the continued rapid response to upcoming CMS quality measures that will hold health systems accountable for inpatient glycemic control..

本轮融资由萨维特资本和海芬资本管理公司领投。这笔重要的资金将推动Glytec平台的持续扩展，包括其旗舰产品Glucommander® SaaS解决方案，加速开发创新新技术以应对日益严重的全球糖尿病及其相关共病的健康危机，并支持对即将到来的CMS质量措施的快速响应，这些措施将使卫生系统对住院患者的血糖控制负责。

Glytec's industry-leading technology platform, trusted by over 400 hospitals, empowers collaborative diabetes management and insulin dosing, improving patient outcomes, reducing hospital length of stay, and optimizing clinical workflows. It's flagship product, Glucommander® -- the first-ever FDA-cleared cloud-based insulin management software -- integrates seamlessly with EMRs, providing advanced clinical decision support, workflow alerts, patient monitoring, and AI-driven analytics.

Glytec行业领先的技术平台受到400多家医院的信任，助力协作式糖尿病管理和胰岛素剂量调整，改善患者预后，缩短住院时间，并优化临床工作流程。其旗舰产品Glucommander® —— 首个获得FDA批准的基于云的胰岛素管理软件 —— 与电子病历系统无缝集成，提供先进的临床决策支持、工作流提醒、患者监测和人工智能驱动的分析。

Supported by over 100 patents and 100 clinical and peer-reviewed publications, Glytec is dedicated to improving metabolic care from hospital to home..

Glytec 依托100多项专利和100多篇临床及同行评审出版物，致力于改善从医院到家庭的代谢护理。